Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product portfolio and clinical testing of its lead asset, and to establish in-house manufacturing capabilities.

DCprime B.V. is backed solely by the Van Herk Group, a Dutch life sciences investor that manages a portfolio of about €1.5 billion ($1.7 billion) of which 10% is invested in private companies directly or as an LP in venture funds including funds from Forbion, Gilde Healthcare and BioGeneration Ventures. ...